A Study of the Use of Molecular Breast Imaging to Evaluate Breast Cancer Tumor Response to Therapy that is Newly Supplemental to Standard Treatment


About this study

The purpose of this study is to evaluate the use of molecular breast imaging as an accurate way to assess the response of breast cancer tumors to chemotherapy or hormone therapy that is newly supplemental to the standard treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Female
  • Has breast cancer
  • Scheduled to undergo neoadjuvant chemotherapy therapy or neoadjuvant hormone therapy
  • Has undergone any breast imaging procedure, and a repeat imaging procedure is planned prior to definite surgery
    • MRI of the breast for accurate tumor size evaluation is recommended but not necessarily required for study inclusion
  • Able to return for a 3-5 week follow-up MBI study and for the final MBI study at completion of the neoadjuvant therapy
  • Age > 18

Exclusion Criteria

  • Unable to understand or sign a consent form
  • Pregnant or lactating
  • Physically unable to sit upright and still for 40 minutes

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Dietlind Wahner-Roedler, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer